Cognition Therapeutics Announced That The First Clinical Trial Site Has Been Activated And Can Begin Recruiting Participants For The 540-patient Phase 2 START Study Of CT1812 In Adults With Early Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics has announced the activation of the first clinical trial site for the Phase 2 START study of CT1812 in adults with early Alzheimer's disease. The site can now begin recruiting participants for the 540-patient study.
July 05, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cognition Therapeutics' announcement of the first clinical trial site activation for the Phase 2 START study of CT1812 could potentially boost investor confidence in the company's progress in developing treatments for Alzheimer's disease.
The activation of the first clinical trial site for the Phase 2 START study of CT1812 signifies progress in Cognition Therapeutics' efforts to develop treatments for Alzheimer's disease. This could potentially boost investor confidence in the company's research and development capabilities, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100